106 related articles for article (PubMed ID: 20051284)
1. The R306G and R506Q mutations in coagulation Factor V reveals additional cleavage sites for Activated Protein C in the R313-R321 region and at R505.
Dirven RJ; Vos HL; Bertina RM
Thromb Res; 2010 May; 125(5):444-50. PubMed ID: 20051284
[TBL] [Abstract][Full Text] [Related]
2. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
3. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
Villoutreix BO; Dahlbäck B
Protein Sci; 1998 Jun; 7(6):1317-25. PubMed ID: 9655335
[TBL] [Abstract][Full Text] [Related]
4. Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679.
van der Neut Kolfschoten M; Dirven RJ; Vos HL; Tans G; Rosing J; Bertina RM
J Biol Chem; 2004 Feb; 279(8):6567-75. PubMed ID: 14660667
[TBL] [Abstract][Full Text] [Related]
5. Identification of an inactivating cleavage site for alpha-thrombin on the heavy chain of factor Va.
Erdogan E; Bukys MA; Orfeo T; Mann KG; Kalafatis M
Thromb Haemost; 2007 Nov; 98(5):998-1006. PubMed ID: 18000604
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
Camire RM; Kalafatis M; Tracy PB
Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
8. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
Tans G; Nicolaes GA; Rosing J
Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
[TBL] [Abstract][Full Text] [Related]
9. The anticoagulant function of coagulation factor V.
Cramer TJ; Gale AJ
Thromb Haemost; 2012 Jan; 107(1):15-21. PubMed ID: 22116556
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C.
Silveira JR; Kalafatis M; Tracy PB
Biochemistry; 2002 Feb; 41(5):1672-80. PubMed ID: 11814362
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance: molecular mechanisms.
Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
[TBL] [Abstract][Full Text] [Related]
12. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa.
Evenäs P; García de Frutos P; Nicolaes GA; Dahlbäck B
Thromb Haemost; 2000 Aug; 84(2):271-7. PubMed ID: 10959700
[TBL] [Abstract][Full Text] [Related]
13. Functional consequences of mutations in amino acid residues that stabilize calcium binding to the first epidermal growth factor homology domain of human protein C.
Geng JP; Cheng CH; Castellino FJ
Thromb Haemost; 1996 Nov; 76(5):720-8. PubMed ID: 8950780
[TBL] [Abstract][Full Text] [Related]
14. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
[TBL] [Abstract][Full Text] [Related]
15. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Dahlbäck B
Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Aparicio C; Dahlbäck B
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
[TBL] [Abstract][Full Text] [Related]
17. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool.
Thomassen MC; Castoldi E; Tans G; Magdeleyns EJ; Delaunoit C; Debusscher L; Van Assche KJ; Rosing J
Haematologica; 2003 Oct; 88(10):1150-6. PubMed ID: 14555311
[TBL] [Abstract][Full Text] [Related]
18. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.
Thorelli E; Kaufman RJ; Dahlbäck B
Blood; 1999 Apr; 93(8):2552-8. PubMed ID: 10194434
[TBL] [Abstract][Full Text] [Related]
19. Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va.
Tran S; Norstrøm E; Dahlbäck B
J Biol Chem; 2008 Mar; 283(11):6648-55. PubMed ID: 18198180
[TBL] [Abstract][Full Text] [Related]
20. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
Dahlbck B
J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
